HCD formulation for cancer treatment
US9682063B2 · kind B2 · utility
0Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 25, 2015 |
| Grant date | Jun 20, 2017 |
| Priority date | — |
| Expiry date | Feb 25, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/5138
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a novel formulation for cancer treatment and a method for enhancing the HCD's efficacy in cancer treatment. Specifically, the present invention provides copper-modified silica nanoparticles loaded with HCD, which exhibits better efficacy than some conventional anticancer drugs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.